Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Sanofi
Biotech
Kymera suffers Sanofi setback but secures $750M Gilead deal
Sanofi is pulling back from its lead IRAK4 degrader, switching to a preclinical prospect, while Gilead has inked an oncology deal with Kymera.
Nick Paul Taylor
Jun 25, 2025 9:31am
Sanofi signs €545M deal to explore Formation’s JAK/SYK inhibitor
Jun 23, 2025 9:47am
Ventyx posts Parkinson's data ahead of potential Sanofi talks
Jun 17, 2025 9:05am
Sanofi vaccine vet vaults to GSK—Chutes & Ladders
Jun 13, 2025 8:30am
GSK snags longtime Sanofi exec to lead vaccine development
Jun 9, 2025 10:45am
Fierce Pharma
Sanofi buys Blueprint for $9.1B, its largest deal in 7 years
Jun 2, 2025 11:09am
